Gastric carcinoma
Conditions
Interventions
200mg, qod,5y Lanreotide 40mg, im, qm,2m
40mg, im, q6m,5y
6 cycles
combined group:Capecitabine 2500 mg/m2/d 2 w, resting 1 w
6 cycles. celecoxb afterward 400mg/d,2m
noncytotoxic drug taken group:celecoxb 400mg/d, 2m
200mg, qod, 5y Lanreotide 40mg, im, qm, 2m
40mg, im, q6m, 5y
chemotherapy group:Capecitabine 2500 mg/m2/d 2 w, resting1 w
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Gastric adenocarcinoma diagnosed by preoperative gastroscope and histopathology test; No peritoneal dissemination or out abdominal cavity metastasis observed by preoperative image analysis; Patients consent to accept gastric carcinoma radical correction aged between 18 and 70; Patients consent to accept preoperative noncytotoxic drug treatment and comment informed consent; Patients reselection on the basis of preoperative selection above mentioned. Postoperative including Criteria: Complete clinical and pathologic data, full registration in gastric carcinoma database; Lymph node scavenge scope D2, over 15 scavenged lymph node; Post operative pathologic diagnosis, staging, over 15 lymph node through pathologic test; Gastric carcinoma by postoperative pathologic diagnose; Willing to attend postoperative clinical research, to comment informed consent.
Exclusion criteria
Exclusion criteria: Preoperative excluding criteria: Drug allergy; Patients stand palliative and extenuative operation, expectant surgery or with remnant gastric cancer and concurrent malignant tumors from other origin;Pregnant women or expect gravidity in five years; Patients suffer from other severe diseases; Patients can not undertake follow-up visit; Postperative excluding criteria:Drug allergy; Less than 15 scavenged lymph node; Remote metastasis, peritoneal dissemination, ovaries metastasis, liver metastasis; Patients stand palliative and extenuative operation, expectant surgery, with out scavenged scope lymph node metastasis or with remnant gastric cancer and concurrent malignant tumors from other origin; Positive findings of exfoliative cytology in abdominal cavity;Stage I, IV gastric carcinoma by clinical pathologic diagnose; Patients can not undertake follow-up visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate;Regional and body recurrence rate;Quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical indicator, immune function,and other markers; | — |
Countries
China
Contacts
Public ContactTang Cheng-Wei
Outcome results
None listed